Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Amgen launched the first U.S. adalimumab biosimilar, Amjevita, in January 2023. Yet according to the latest findings from Spherix Global Insights,...
Genentech's Vabysmo got an 18-month head start over Regeneron's high dose Eylea (8mg aflibercept), but that lead time may be coming to a close within ...
Prior to Ferring Pharmaceuticals' Rebyota, physicians interested in using fecal microbiota transplants (FMT) to treat patients with recurrent...
The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S....
In March of 2022, the FDA approved AbbVie's JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC)....
Spherix Global Insights, a leading provider of market research, business intelligence and advisory services to the global life sciences industry,...
According to the Lupus Foundation of America, approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus (SLE)...
In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC)...
Spherix Global Insights recently released data from their Launch Dynamix™: Trudhesa in Acute Treatment of Migraine (US) deep dive study tracking the...
With the accelerated approval on January 6, 2023 for early Alzheimer's disease, Eisai/Biogen's Leqembi (lecanemab-irmb) became only the second...
In 2017, Sanofi/Regeneron announced the FDA approval for the first biologic agent to treat atopic dermatitis (AD). The success of that drug, Dupixent ...
According to Spherix Global Insights' Launch Dynamix™: Vabysmo service, to no surprise, Regeneron's Eylea continues to lead the charge in both the...
In the 32nd wave of ongoing tracking of the U.S. Renal Anemia market, Spherix surveyed 207 US nephrologists about overall patient management and...
In 2021, Eli Lilly ("Lilly") announced it would forego pursuing a psoriasis indication for its IL-23 inhibitor mirikizumab, strategically focusing...
When the FDA approved Rebyota, a new class of Clostridioides Difficile (C.diff) treatment, Ferring Pharmaceuticals ushered in the first significant...
Spherix Global Insights recently released data from their Launch Dynamix™: Qulipta for Migraine Prevention (US) deep dive study tracking the launch...
Focus on glomerular diseases has intensified over the past few years as products have advanced in development and nephrologists increasingly identify ...
With the U.S. commercial launch of TG Therapeutics' Briumvi (ublituximab-xiiy) on January 26th, 2023 for the treatment of relapsing multiple...
With the FDA approval of Amylyx's Relyvrio (AMX0035; sodium phenylbutyrate and taurursodiol) for amyotrophic lateral sclerosis (ALS) in September...
On February 16, The Lancet Neurology published the Phase 3 results of Pfizer's zavegepant for the acute treatment of migraine. The CGRP receptor...
Apellis Pharmaceuticals recently made history with the approval of Syfovre (pegcetacoplan) for the treatment for Geographic Atrophy (GA). GA is an...
Last summer, the introduction of biosimilar agents into ophthalmologists' armamentarium was a big event in the United States medical community....
Argenx's launch of Vyvgart (efgartigimod) has been a success, with global first-year revenue of ~$400 million USD. As the second biologic approved...
Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) given the wide heterogeneity of the disease ...
According to Biogen's earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third year in a ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.